New insights on cardiometabolic risk management

Objectives of the meeting

A significant number of patients with cardiovascular disease (CVD) have concomitant metabolic comorbidities which play a causal and/or permissive role in adverse prognosis.

• The primary objective of the meeting is to improve the recognition and treatment of CVD in patients with multiple metabolic comorbidities. 
• The meeting also aims to assess potential mechanism-based approaches to intervention across multiple disorders.

Questions to be addressed

• How can we improve recognition and treatment of cardiovascular disease in patients with obesity, insulin resistance, NASH, and renal disease when associated with metabolic comorbidity?
• How can we improve the recognition and treatment of metabolic and renal disease in patients at the cardiology clinic?
• Are there mechanism-based approaches that can address multiple pathologies across diseases?
• What is important to patients with cardiovascular and metabolic diseases? How can we meet their needs?
• Why may COVID-19 be particularly damaging for patients with cardiovascular and metabolic disease?
• Can we move from broad regulatory definitions to better targeting patients with multiple comorbidities?

Programme

• 09:00–09:10 - Welcome – Introduction and objectives of the meeting by Chairpersons
• 09:10–09:40 - Session I: Common soil and common targets for CKD, NASH and HF? (10 min presentations)
  • The epidemiological basis by Prof. Philip Newsome (Birmingham) (via Zoom)
  • What are the biological underpinnings of the relationship between metabolic and cardiovascular disease? by Prof. Faiez Zannad (Nancy)
  • What are the clinical and practical implications for physicians as it relates to this interface? by Prof. Per-Henrik Groop (Helsinki)
• 09:40–10:00 - Discussion
• 10:00–10:30 - Session II: Unravelling the relationships between obesity and CKD in patients with CV disease (10 min presentations)
  • Epidemiology and natural history of this relationship by Prof. Paola Fioretto (Padova)
  • Obesity and HFpEF – common soil? by Prof. Lars Lund (Stockholm) (via Zoom)
  • Obesity paradox by Prof. Stefan Anker (Berlin)
• 10:30–10:45 - Discussion
• 10:45–11:05 - Break
• 11:05–11:35 - Session III: COVID-19 – a new threat at the cross-roads between cardiovascular and metabolic diseases (10 min presentations)
  • How metabolic derangements affect the incidence and natural history of COVID-19 by Prof. Naveed Sattar (Glasgow) (via Zoom)
  • CV derangement in COVID-19 by Prof. Scott S. Solomon (Boston)
  • What are the practical management implications of cardiometabolic disease in patients with COVID-19 by Prof. Kamlesh Khunti (Leicester)
• 11:35–12:00 - Discussion
• 12:00–12:15 - Session IV: A patient’s perspective on heart failure, renal disease and diabetes
  • Canadian patient (video)
  • ESC patient – Mr Paul McGreavy (UK) (10 min presentation)
• 12:15–12:45 - Discussion
• 12:45–13:45 - Lunch
• 13:45–14:15 - Session V: Mechanisms of chronic cardiometabolic diseases and opportunities for intervention (10 min presentations)
  • Sex differences in cardiometabolic risk and opportunities for intervention by Dr. Carolyn Sp Lam (Singapore) (via Zoom)
  • Circulating biomarkers and their utility in cardiometabolic disease by Prof. Andreas M. Zeiher (Frankfurt)
  • Reversal of Pro-vascular Regenerative Cell Exhaustion in Diabetes and Obesity by Dr. David Hess (Toronto)
• 14:15–14:35 - Discussion
• 14:35–14:55 - Lecture: Health and economics consequences of obesity by Prof. Michele Cecchini (OECD)
  • Questions to be addressed: What have we learnt from GBD study? What do we need to do to stem the tide?
• 14:55–16:00 - Panel discussion
• 16:00 - Wrap-up – Next steps – A publication